18 results
S-3
EX-1.2
BOLT
Bolt Biotherapeutics Inc
30 Mar 22
Shelf registration
5:14pm
, in accordance with the provisions of Section 11 hereunder, will pay the following expenses all incident to the performance of its obligations hereunder
10-K
2020 FY
BOLT
Bolt Biotherapeutics Inc
31 Mar 21
Annual report
4:06pm
cohort. These dose levels were well tolerated by all four patients and they completed the safety evaluation period without incident. Neither dose
424B4
BOLT
Bolt Biotherapeutics Inc
5 Feb 21
Prospectus supplement with pricing info
4:44pm
were well tolerated by all four patients and they completed the safety evaluation period without incident. Neither dose was expected
S-1/A
1cjdr
1 Feb 21
IPO registration (amended)
6:24am
S-1/A
EX-1.1
ahefn
1 Feb 21
IPO registration (amended)
6:24am
S-1
EX-3.3
vxc4wf
15 Jan 21
IPO registration
3:58pm
S-1
EX-3.4
w2dw73n5
15 Jan 21
IPO registration
3:58pm
S-1
6ltfr
15 Jan 21
IPO registration
3:58pm
S-1
EX-10.18
1nvnb 7lvdr
15 Jan 21
IPO registration
3:58pm
S-1
EX-10.19
5gz3qan
15 Jan 21
IPO registration
3:58pm
S-1
EX-10.17
gd9k16msiqh61
15 Jan 21
IPO registration
3:58pm
DRS/A
EX-3.3
qb2f28v
11 Sep 20
Draft registration statement (amended)
12:00am
DRS/A
EX-10.19
37x3138hhja8e0mxu2cn
11 Sep 20
Draft registration statement (amended)
12:00am
DRS/A
EX-10.18
bxibgw9
11 Sep 20
Draft registration statement (amended)
12:00am
DRS/A
EX-10.17
d7ll052
11 Sep 20
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next